These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25487273)

  • 1. Intellectual property education exemplified by the patents on the CRISPR/Cas9 system.
    Fan X; Liao G; Xie J
    Yi Chuan; 2014 Dec; 36(12):1269-73. PubMed ID: 25487273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR as a driving force: the Model T of biotechnology.
    Mariscal C; Petropanagos A
    Monash Bioeth Rev; 2016 Jun; 34(2):101-116. PubMed ID: 27619650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-editing technologies and patent landscape overview.
    Benahmed-Miniuk F; Kresz M; Kanaujiya JK; Southgate CD
    Pharm Pat Anal; 2017 May; 6(3):115-134. PubMed ID: 28534435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Progress in CRISPR/Cas9 Technology.
    Mei Y; Wang Y; Chen H; Sun ZS; Ju XD
    J Genet Genomics; 2016 Feb; 43(2):63-75. PubMed ID: 26924689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diversity and evolution of class 2 CRISPR-Cas systems.
    Shmakov S; Smargon A; Scott D; Cox D; Pyzocha N; Yan W; Abudayyeh OO; Gootenberg JS; Makarova KS; Wolf YI; Severinov K; Zhang F; Koonin EV
    Nat Rev Microbiol; 2017 Mar; 15(3):169-182. PubMed ID: 28111461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The big bang of genome editing technology: development and application of the CRISPR/Cas9 system in disease animal models.
    Shao M; Xu TR; Chen CS
    Dongwuxue Yanjiu; 2016 Jul; 37(4):191-204. PubMed ID: 27469250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila.
    Xu J; Ren X; Sun J; Wang X; Qiao HH; Xu BW; Liu LP; Ni JQ
    J Genet Genomics; 2015 Apr; 42(4):141-9. PubMed ID: 25953352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The application of CRISPR/Cas9 in genome editing of filamentous fungi.
    Li HH; Liu G
    Yi Chuan; 2017 May; 39(5):355-367. PubMed ID: 28487268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome editing: intellectual property and product development in plant biotechnology.
    Schinkel H; Schillberg S
    Plant Cell Rep; 2016 Jul; 35(7):1487-91. PubMed ID: 27146974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9: an advanced tool for editing plant genomes.
    Samanta MK; Dey A; Gayen S
    Transgenic Res; 2016 Oct; 25(5):561-73. PubMed ID: 27012546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Overview of patents on targeted genome editing technologies and their implications for innovation and entrepreneurship education in universities].
    Fan XY; Lin YP; Liao GJ; Xie JP
    Yi Chuan; 2015 Dec; 37(12):1258-62. PubMed ID: 26704951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Building the Class 2 CRISPR-Cas Arsenal.
    Lewis KM; Ke A
    Mol Cell; 2017 Feb; 65(3):377-379. PubMed ID: 28157502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dealing with Patent Fragmentation in Genetics: Can Patent Pools Facilitate the Development of CRISPR Gene-Editing Technology?
    Stasi A; Rodrigues IP
    J Law Med; 2019 Jul; 26(4):866-873. PubMed ID: 31682364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New variants of CRISPR RNA-guided genome editing enzymes.
    Murovec J; Pirc Ž; Yang B
    Plant Biotechnol J; 2017 Aug; 15(8):917-926. PubMed ID: 28371222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the genome editing tool CRISPR/Cas9 in non-human primates.
    Luo X; Li M; Su B
    Dongwuxue Yanjiu; 2016 Jul; 37(4):214-9. PubMed ID: 27469252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research progress in the third-generation genomic editing technology - CRISPR/Cas9].
    Zhou Y; Zong Y; Kong X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2016 Oct; 33(5):713-6. PubMed ID: 27577230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas9 claim sets and the potential to stifle innovation.
    Gray BN; Spruill WM
    Nat Biotechnol; 2017 Jul; 35(7):630-633. PubMed ID: 28700549
    [No Abstract]   [Full Text] [Related]  

  • 18. CRISPR-Cas9: from Genome Editing to Cancer Research.
    Chen S; Sun H; Miao K; Deng CX
    Int J Biol Sci; 2016; 12(12):1427-1436. PubMed ID: 27994508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the potential of genome editing CRISPR-Cas9 technology.
    Singh V; Braddick D; Dhar PK
    Gene; 2017 Jan; 599():1-18. PubMed ID: 27836667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Will the CRISPR / CAS9 system change the genome of humanity?].
    Becú-Villalobos D
    Medicina (B Aires); 2017; 77(6):521-523. PubMed ID: 29223949
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.